These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10202211)

  • 21. Tachykinin receptors as drug targets for motility disorders.
    Hoogerwerf WA; Sarna SK
    Dig Dis; 2006; 24(1-2):83-90. PubMed ID: 16699266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological treatment of irritable bowel syndrome--from concept to sales.
    Kamm MA
    Eur J Surg Suppl; 2002; (587):10-5. PubMed ID: 16144196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Irritable colon. Physiopathologic and therapeutic aspects].
    Cammarella I; Ruggeri R; Musca A
    Clin Ter; 1992 May; 140(5):473-80. PubMed ID: 1424487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolving pathophysiological model of functional gastrointestinal disorders: implications for treatment.
    Mayer EA; Naliboff BD; Chang L
    Eur J Surg Suppl; 2002; (587):3-9. PubMed ID: 16144195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Postoperative ileus: part I (Experimental results)].
    Kasparek MS; Kreis ME; Jehle EC; Zittel TT
    Zentralbl Chir; 2003 Apr; 128(4):313-9. PubMed ID: 12700989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tegaserod and other serotonergic agents: what is the evidence?
    Chey WD
    Rev Gastroenterol Disord; 2003; 3 Suppl 2():S35-40. PubMed ID: 12776001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cisapride and other prokinetic agents in the treatment of gastroenterological diseases].
    Ryss ES; Fishzon-Ryss IuI
    Ter Arkh; 1995; 67(2):58-61. PubMed ID: 7725263
    [No Abstract]   [Full Text] [Related]  

  • 28. New developments in the treatment of irritable bowel syndrome.
    De Schryver AM; Samsom M
    Scand J Gastroenterol Suppl; 2000; (232):38-42. PubMed ID: 11232489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.
    Gershon MD
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():3-14. PubMed ID: 15521849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serotonin and dopamine interactions in psychosis prevention.
    Richtand NM; McNamara RK
    Prog Brain Res; 2008; 172():141-53. PubMed ID: 18772031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Irritable bowel syndrome as an interdisciplinary clinical challenge. Current views on its pathophysiology, diagnosis and treatment].
    Hollerbach S; Elsenbruch S; Enck P
    Dtsch Med Wochenschr; 2001 Apr; 126(16):472-8. PubMed ID: 11360454
    [No Abstract]   [Full Text] [Related]  

  • 32. Motility-like dyspepsia. Current concepts in pathogenesis, investigation and management.
    Kellow JE
    Med J Aust; 1992 Sep; 157(6):385-8. PubMed ID: 1447988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drugs acting on serotonin receptors for the treatment of functional GI disorders.
    Tonini M; Pace F
    Dig Dis; 2006; 24(1-2):59-69. PubMed ID: 16699264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abdominal pain in Irritable Bowel Syndrome: a review of putative psychological, neural and neuro-immune mechanisms.
    Elsenbruch S
    Brain Behav Immun; 2011 Mar; 25(3):386-94. PubMed ID: 21094682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The gut as a neurological organ.
    Holzer P; Schicho R; Holzer-Petsche U; Lippe IT
    Wien Klin Wochenschr; 2001 Sep; 113(17-18):647-60. PubMed ID: 11603099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Gastrointestinal motility disorders and drugs: opioids, calcium antagonists, nitrates, peptides, prostaglandins and 5-hydroxytryptaminergic drugs (part II)].
    Jovanović-Mićić D; Samardzić R; Beleslin B
    Srp Arh Celok Lek; 1994; 122(3-4):88-92. PubMed ID: 17972818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Functional colonic diseases: from physiopathology to pharmacology].
    Bardou M
    Rev Med Interne; 1999 Feb; 20(2):151-7. PubMed ID: 10227093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review article: evaluation of drugs in experimental gut distension models.
    Pappas TN; Mangel AW; Lawson C
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():54-6. PubMed ID: 10429741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Irritable bowel syndrome: pathophysiology and (future) treatment options].
    de Schryver AM; Samsom M
    Ned Tijdschr Geneeskd; 2002 Jan; 146(1):12-7. PubMed ID: 11802330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Visceral hypersensitivity in irritable bowel syndrome.
    Kanazawa M; Hongo M; Fukudo S
    J Gastroenterol Hepatol; 2011 Apr; 26 Suppl 3():119-21. PubMed ID: 21443723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.